nach oben

Erschienen in:

08.11.2017 | Original Article

Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer

verfasst von: Qin Li, Tielong Tang, Peng Zhang, Chenlu Liu, Yan Pu, Yan Zhang, Huizi Song, Yanyun Wang, Yaping Song, Min Su, Bin Zhou, Lin Zhang

Erschienen in: Familial Cancer | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-31 is a crucial cytokine triggering inflammation which could be one of the risk factors of tumors. However, data for correlation between IL-31 and tumors are limited. The purpose of our study was to discuss whether genetic polymorphisms of IL-31 were associated with the susceptibility and clinical outcomes of bladder cancer. Our study enrolled 478 controls, 156 non-muscle-invasive bladder cancer (NMIBC) and 138 muscle-invasive bladder cancer (MIBC) patients. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping two single nucleotide polymorphisms (SNPs) of IL-31 gene including rs7977932 and rs4758680. Our results showed that A allele and CA/AA genotypes of rs4758680 were associated with susceptibility to bladder cancer (P = 0.04, OR 1.32, 95% CI 1.01–1.72, and P = 0.02, OR 1.43, 95% CI 1.05–1.96, respectively), and G allele of rs7977932 might be a protect factor for tobacco smoking patients compared with non-smoking patients (P = 0.005, OR 0.42, 95% CI 0.23–0.76). Furthermore, CA/AA genotypes of rs4758680 might be the independent risk factors for the decreased recurrence-free survival of the patients with MIBC (P = 0.03, OR 2.02, 95% CI 1.06–3.85. Our data indicated that polymorphisms of IL-31 are associated with bladder cancer, and rs4758680 could be an independent prediction for MIBC patients with a high risk of recurrence.

El-Arabey AA (2017) New insight for metformin against bladder cancer. Genes Environ 39:13. https://doi.org/10.1186/s41021-017-0074-z CrossRefPubMedPubMedCentral

Zhang Y, Sun Y, Chen T et al (2014) Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population. Int J Mol Sci 15(11):19330–19341. https://doi.org/10.3390/ijms151119330 CrossRefPubMedPubMedCentral

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):9CrossRef

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA 65(1):5–29 https://doi.org/10.3322/caac.21254 CrossRefPubMed

Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241. https://doi.org/10.1016/j.eururo.2012.07.033 CrossRefPubMed

Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V (2010) Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 193(2):131–137CrossRef

Sonkoly E, Muller A, Lauerma AI et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411–417CrossRef

Cornelissen C, Luscher-Firzlaff J, Baron JM, Luscher B (2012) Signaling by IL-31 and functional consequences. Eur J Cell Biol 91(6–7):552–566CrossRef

10.

Knight D, Mutsaers SE, Prele CM (2011) STAT3 in tissue fibrosis: is there a role in the lung? Pulm Pharmacol Ther 24(2):193–198CrossRef

11.

Ouyang H, Cheng J, Zheng Y, Du J (2014) Role of IL-31 in regulation of Th2 cytokine levels in patients with nasal polyps. Eur Archiv Oto-rhino-laryngol 271(10):2703–2709. https://doi.org/10.1007/s00405-014-2913-x CrossRef

12.

Tseng WN, Lo MH, Guo MM, Hsieh KS, Chang WC, Kuo HC (2014) IL-31 associated with coronary artery lesion formation in Kawasaki disease. PloS ONE 9(8):e105195. https://doi.org/10.1371/journal.pone.0105195 CrossRefPubMedPubMedCentral

13.

Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW (2010) Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22(6):453–467. https://doi.org/10.1093/intimm/dxq027 CrossRefPubMed

14.

Yagi Y, Andoh A, Nishida A et al (2007) Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med 19(6):941–946PubMed

15.

Lan CC, Tu HP, Wu CS et al (2011) Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population. Exp Dermatol 20(12):975–979. https://doi.org/10.1111/j.1600-0625.2011.01374.x CrossRefPubMed

16.

Huang HT, Chen JM, Guo J, Lan Y, Wei YS (2016) The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol Int 36(6):799–805. https://doi.org/10.1007/s00296-016-3422-6 CrossRefPubMed

17.

Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW (2007) Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology 122(4):532–541. https://doi.org/10.1111/j.1365-2567.2007.02668.x CrossRefPubMedPubMedCentral

18.

Zeng X, Zhang Z, Gao QQ et al (2016) Clinical significance of serum interleukin-31 and interleukin-33 levels in patients of endometrial cancer: a case control study. Dis Markers 2016:9262919 https://doi.org/10.1155/2016/9262919 CrossRefPubMedPubMedCentral

19.

Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2012) Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Exp Oncol 34(4):348–353PubMed

20.

Hirao Y, Kim WJ, Fujimoto K (2009) Environmental factors promoting bladder cancer. Curr Opin Urol 19(5):494–499CrossRef

21.

Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22(15):1928–1929CrossRef

22.

Dupont WD, Plummer WD Jr. (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11(2):116–128CrossRef

23.

Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A (2014) International variations in bladder cancer incidence and mortality. Eur Urol 66(1):59–73. https://doi.org/10.1016/j.eururo.2013.10.001 CrossRefPubMed

24.

Gandini S, Botteri E, Iodice S et al (2008) Tobacco smoking and cancer: a meta-analysis. Int J Cancer 122(1):155–164. https://doi.org/10.1002/ijc.23033 CrossRefPubMed

25.

Vineis P, Talaska G, Malaveille C et al (1996) DNA adducts in urothelial cells:relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 65(3):314–316. https://doi.org/10.1002/(SICI)1097-0215(19960126)65:3<314::AID-IJC6>3.0.CO;2-2 CrossRefPubMed

26.

Corral R, Lewinger JP, Van Den Berg D et al (2014) Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int J Cancer 135(2):335–347. https://doi.org/10.1002/ijc.28693 CrossRefPubMedPubMedCentral

27.

Cornelissen C, Brans R, Czaja K et al (2011) Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells. Br J Dermatol 165(5):966–975CrossRef

28.

Niyonsaba F, Ushio H, Hara M et al (2010) Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 184(7):3526–3534CrossRef

29.

Ishii T, Wang J, Zhang W et al (2009) Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 113(23):5942–5950PubMed

30.

Siraganian RP (2003) Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol 15(6):639–646CrossRef

31.

Bilsborough J, Leung DY, Maurer M et al (2006) IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117(2):418–425CrossRef

32.

Raap U, Wichmann K, Bruder M et al (2008) Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122(2):421–423. https://doi.org/10.1016/j.jaci.2008.05.047 CrossRefPubMed

33.

Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y (2008) Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 14(33):5154–5161CrossRef

34.

Dambacher J, Beigel F, Seiderer J et al (2007) Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut 56(9):1257–1265CrossRef

35.

Lei Z, Liu G, Huang Q et al (2008) SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 63(3):327–332CrossRef

36.

Okano M, Fujiwara T, Higaki T et al (2011) Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis. J Allergy Clin Immunol 127(1):277-9, 279.e1-11. https://doi.org/10.1016/j.jaci.2010.09.029 CrossRef

37.

Malek M, Glen J, Rebala K et al (2015) Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. Acta Derm Venereol 95(3):283–288. https://doi.org/10.2340/00015555-1958 CrossRefPubMed

38.

Nattkemper LA, Martinez-Escala ME, Gelman AB et al (2016) Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol 96(7):894–898. https://doi.org/10.2340/00015555-2417 CrossRefPubMed

39.

Ferretti E, Tripodo C, Pagnan G et al (2015) The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia 29(4):958–967. https://doi.org/10.1038/leu.2014.291 CrossRefPubMed

40.

Lange M, Glen J, Zablotna M et al (2017) Interleukin-31 polymorphisms and serum IL-31 level in patients with mastocytosis: correlation with clinical presen-tation and pruritus. Acta Derm Venereol 97(1):47–53. https://doi.org/10.2340/00015555-2474 CrossRefPubMed

41.

Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95(3):497–505. https://doi.org/10.1002/jcb.20477 CrossRefPubMed

42.

Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W (2008) Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 19(5–6):347–356. https://doi.org/10.1016/j.cytogfr.2008.08.003 CrossRefPubMedPubMedCentral

43.

Rizner TL (2016) Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Rev Mol Diagn 16(12):1315–1336. https://doi.org/10.1080/14737159.2016.1258302 CrossRefPubMed

Titel: Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer
verfasst von: Qin Li
Tielong Tang
Peng Zhang
Chenlu Liu
Yan Pu
Yan Zhang
Huizi Song
Yanyun Wang
Yaping Song
Min Su
Bin Zhou
Lin Zhang
Publikationsdatum: 08.11.2017
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-017-0060-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

APC mosaicism in a young woman with desmoid type fibromatosis and familial adenomatous polyposis

Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers

Discussions about predictive genetic testing for Lynch syndrome: the role of health professionals and families in decisions to decline

Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation

Mutations in context: implications of BRCA testing in diverse populations

Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie